ClinicalTrials.gg
Enrolling by invitationNCT06595615Updated Apr 3, 2026

Health App Data Collection Study

An observational study in Cardiac Disease, sponsored by Abbott Medical Devices. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Abbott Medical Devices (part of Abbott) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies in Heart Diseases by Abbott — 5 open to participants now, 5 under way, none of them phase 3. Heart Diseases · Abbott.

Started
2025
with 1 other
Observational
6 of 15
2 open now
Registered
13th of 15
by date

Among the 15 studies in Heart Diseases by Abbott, this one is one of 2 that started in 2025, is one of 6 observational ones, and was the 13th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 251 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

5 of the 15 studies in Heart Diseases by Abbott are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 129 (71%) set no upper age limit and 21 (12%) stop at 75 or younger; 33 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Heart Diseases by Abbott, or all of them as a file.
02

Study summary

Utilization of additional wearable data to improve clinical outcome

Read the detailed description

In addition to information available from cardiac implantable medical devices, health related data available from commercially approved wearables and devices such as Apple watch, blood pressure monitor and scales could be used to improve predictive analytics of impending clinical events. This study is to merge implantable medical device data with wearable data to evaluate the added benefit of extra data.

03

Conditions studied

  • Cardiac Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients indicated for cardiac implantable medical devices

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients are willing to be compliant with daily measurements required 18 years of age or older
  • Patients who have been implanted with ABT CRT-D devices connected to Merlin.net
  • Patients who had at least one HF clinical event during past 12 calendar months
  • Must provide written prior to the commencement of this clinical feasibility study
  • Patients are willing to be compliant with daily measurements required

Exclusion criteria

Exclusion Criteria:

  • Pregnant and/or lactating mothers will be excluded from the study or have a plan to be pregnant in the next 12 months
  • Patients with a less than the duration of the study, as per clinician's discretion.
  • Patients who will not be able to complete the daily survey questions due to inability to read
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Interventions

  • Devicecardiovascular implantable electronic devices

    Standard of care patients indicated for the devices

06

What researchers measure

Primary outcomes

  1. Acquisition of additional health data using patient App

    Health data acquisition via an app from multiple wearables and externals.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jan 2027, 21 months after the start.

Of 54 industry-sponsored observational studies under Heart Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 65. This study's planned 21 months is below that.

Counting every sponsor, half of 239 studies reached it within 46 months; a quarter within 18 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2024
First posted
Sep 19, 2024
StartActual
Apr 9, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Dec 2027
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06595615
Collaborators
Huntsville Hospital Health System
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Apr 9, 2025
Primary completion
Jan 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion